Daniel Markowitz
Stock Analyst at Evercore ISI Group
(1.51)
# 4,060
Out of 5,182 analysts
31
Total ratings
25%
Success rate
-9.79%
Average return
Main Sectors:
Stocks Rated by Daniel Markowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MMED Minimed Group | Initiates: Outperform | $20 | $14.01 | +42.76% | 1 | Mar 31, 2026 | |
| NTRA Natera | Maintains: Outperform | $250 → $260 | $207.98 | +25.01% | 3 | Feb 27, 2026 | |
| TMDX TransMedics Group | Maintains: Outperform | $155 → $170 | $100.70 | +68.83% | 2 | Feb 25, 2026 | |
| RGEN Repligen | Maintains: Outperform | $180 → $170 | $117.78 | +44.34% | 5 | Feb 25, 2026 | |
| GH Guardant Health | Maintains: In-Line | $105 → $110 | $93.83 | +17.23% | 4 | Feb 20, 2026 | |
| PODD Insulet | Maintains: Outperform | $370 → $340 | $204.31 | +66.41% | 2 | Feb 19, 2026 | |
| TECH Bio-Techne | Maintains: In-Line | $62 → $68 | $53.13 | +27.99% | 4 | Feb 5, 2026 | |
| WST West Pharmaceutical Services | Maintains: Outperform | $390 → $320 | $254.80 | +25.59% | 4 | Feb 3, 2026 | |
| RMBS Rambus | Maintains: Outperform | $126 → $119 | $93.03 | +27.92% | 3 | Feb 3, 2026 | |
| DXCM DexCom | Initiates: In-Line | $68 | $62.22 | +9.29% | 1 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $125 | $54.99 | +127.31% | 2 | Oct 7, 2025 |
Minimed Group
Mar 31, 2026
Initiates: Outperform
Price Target: $20
Current: $14.01
Upside: +42.76%
Natera
Feb 27, 2026
Maintains: Outperform
Price Target: $250 → $260
Current: $207.98
Upside: +25.01%
TransMedics Group
Feb 25, 2026
Maintains: Outperform
Price Target: $155 → $170
Current: $100.70
Upside: +68.83%
Repligen
Feb 25, 2026
Maintains: Outperform
Price Target: $180 → $170
Current: $117.78
Upside: +44.34%
Guardant Health
Feb 20, 2026
Maintains: In-Line
Price Target: $105 → $110
Current: $93.83
Upside: +17.23%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $370 → $340
Current: $204.31
Upside: +66.41%
Bio-Techne
Feb 5, 2026
Maintains: In-Line
Price Target: $62 → $68
Current: $53.13
Upside: +27.99%
West Pharmaceutical Services
Feb 3, 2026
Maintains: Outperform
Price Target: $390 → $320
Current: $254.80
Upside: +25.59%
Rambus
Feb 3, 2026
Maintains: Outperform
Price Target: $126 → $119
Current: $93.03
Upside: +27.92%
DexCom
Nov 25, 2025
Initiates: In-Line
Price Target: $68
Current: $62.22
Upside: +9.29%
Oct 7, 2025
Maintains: Outperform
Price Target: $150 → $125
Current: $54.99
Upside: +127.31%